CoChat

Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Abstract

Purpose of review We discuss current controversies in the clinical use of omega-3 fatty acids (FA), primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and examine discrepancies between recent trials. Furthermore, we discuss potential side effects reported in these studies and the role of mixed omega-3 FA dietary supplements and concerns about their use.Recent findings REDUCE-IT showed that addition of icosapent ethyl, a highly purified form of EPA, can reduce risk of cardiovascular events among statin-treated individuals with high triglycerides. Additional supportive evidence for EPA has come from other trials and meta-analyses of omega-3 FA therapy. In contrast, trials of mixed EPA/DHA products have consistently failed to improve cardiovascular outcomes. Discrepancies in results reported in RCTs could be explained by differences in omega-3 FA products, dosing, study populations, and study designs including the placebo control formulation. Evidence obtained from highly purified forms should not be extrapolated to other mixed formulations, including "over-the-counter" omega-3 supplements. Targeting TG-rich lipoproteins represents a new frontier for mitigating ASCVD risk. Clinical and basic research evidence suggests that the use of omega-3 FA, specifically EPA, appears to slow atherosclerosis by reducing triglyceride-rich lipoproteins and/or inflammation, therefore addressing residual risk of clinical ASCVD.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11883-022-01031-9

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 80 references

Cited by

See all 19

Metadata

Authors
Quispe, R., Alfaddagh, A., Kazzi, B., Zghyer, F., Marvel, F. A., Blumenthal, R. S., Sharma, G., & Martin, S. S.
Affiliations
Johns Hopkins University (US)
Corresponding author
Martin, Seth S.
Venue
Current Atherosclerosis Reports
Published
2022-04-30
Volume
24
Issue
7
Pages
571-581
ISSN
  • 1523-3804 (ISSN-L)
  • 1534-6242
OpenAlex
W4225263789
Cited by
17
References
80
Citations by year
2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 1
FWCI
0.54
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Atherosclerosis Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
Keywords
omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, icosapent ethyl, atherosclerosis prevention, cardiovascular disease, triglyceride-rich lipoproteins, triglyceride elevation, statin-treated patients, over-the-counter supplements, residual cardiovascular risk, inflammation, adverse effects
MeSH terms
Cardiovascular Diseases, Docosahexaenoic Acids, Humans, Triglycerides, Hypertriglyceridemia, Fatty Acids, Omega-3, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dietary Supplements, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis. https://app.cochat.ai/papers/10.1007/s11883-022-01031-9
The paper
Quispe, R., Alfaddagh, A., Kazzi, B., Zghyer, F., Marvel, F. A., Blumenthal, R. S., Sharma, G., & Martin, S. S. (2022). Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-022-01031-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.